Literature DB >> 22045485

Interrelations between CSF soluble AβPPβ, amyloid-β 1-42, SORL1, and tau levels in Alzheimer's disease.

Panagiotis Alexopoulos1, Liang-Hao Guo, Amalia Tsolakidou, Martina Kratzer, Timo Grimmer, Christine Westerteicher, Meizi Jiang, Hideaki Bujo, Janine Diehl-Schmid, Alexander Kurz, Robert Perneczky.   

Abstract

Recently, light has been shed on possible interrelations between the two most important pathological hallmarks of Alzheimer's disease (AD): the amyloid cascade and axonal degeneration. In this study, we investigated associations between sβAPPβ, a product of the cleavage of the amyloid-β protein precursor (AβPP) by β-secretase, amyloid-β 1-42 (Aβ42), soluble SORL1 (also called LR11 or SORLA), a receptor that is involved in AβPP processing, and the marker of axonal degeneration tau in the cerebrospinal fluid (CSF) of 76 patients with mild cognitive impairment (MCI), 61 patients with AD, and 17 patients with frontotemporal dementia, which neuropathologically is not related to the amyloid pathology. In the AD group, significant associations between sAβPPβ, tau (p < 0.001), and soluble SORL1 (p < 0.001) were detected according to linear regression models. In patients with MCI, sAβPPβ correlated significantly with tau (p < 0.001) and soluble SORL1 (p = 0.003). In the FTD group, only SORL1 (p = 0.011) was associated with sAβPPβ and not tau. Aβ42 was found to be significantly related to tau levels in CSF in the MCI group (p < 0.001) and they tended to be associated in the AD group (p = 0.05). Our results provide further evidence for a link between the two facets of AD pathology, which is likely to be mediated by the binding of Aβ oligomers to specifically targeted neurons, resulting in stimulating tau hyperphosphorylation and neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22045485     DOI: 10.3233/JAD-2011-110983

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  13 in total

Review 1.  The role of the retromer complex in aging-related neurodegeneration: a molecular and genomic review.

Authors:  Christiane Reitz
Journal:  Mol Genet Genomics       Date:  2014-10-21       Impact factor: 3.291

2.  Association of the top 20 Alzheimer's disease risk genes with [18F]flortaucipir PET.

Authors:  Eddie Stage; Shannon L Risacher; Kathleen A Lane; Sujuan Gao; Kwangsik Nho; Andrew J Saykin; Liana G Apostolova
Journal:  Alzheimers Dement (Amst)       Date:  2022-05-11

Review 3.  Biomarker modelling of early molecular changes in Alzheimer's disease.

Authors:  Ross W Paterson; Jamie Toombs; Catherine F Slattery; Jonathan M Schott; Henrik Zetterberg
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

Review 4.  Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease.

Authors:  Anne M Fagan; Richard J Perrin
Journal:  Biomark Med       Date:  2012-08       Impact factor: 2.851

Review 5.  Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Authors:  Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber
Journal:  World J Biol Psychiatry       Date:  2017-10-27       Impact factor: 4.132

6.  The role of intracellular trafficking and the VPS10d receptors in Alzheimer's disease.

Authors:  Christiane Reitz
Journal:  Future Neurol       Date:  2012-07-01

7.  Elevated YKL-40 and low sAPPβ:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD.

Authors:  Daniel Alcolea; David J Irwin; Ignacio Illán-Gala; Laia Muñoz; Jordi Clarimón; Corey T McMillan; Juan Fortea; Rafael Blesa; Edward B Lee; John Q Trojanowski; Murray Grossman; Alberto Lleó
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-10-08       Impact factor: 10.154

8.  Associations of the Top 20 Alzheimer Disease Risk Variants With Brain Amyloidosis.

Authors:  Liana G Apostolova; Shannon L Risacher; Tugce Duran; Eddie C Stage; Naira Goukasian; John D West; Triet M Do; Jonathan Grotts; Holly Wilhalme; Kwangsik Nho; Meredith Phillips; David Elashoff; Andrew J Saykin
Journal:  JAMA Neurol       Date:  2018-03-01       Impact factor: 18.302

9.  Soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for differential diagnosis of mild cognitive impairment.

Authors:  Wataru Araki; Kazutomi Kanemaru; Kotaro Hattori; Tadashi Tsukamoto; Yuko Saito; Sumiko Yoshida; Harumasa Takano; Masuhiro Sakata; Yuma Yokoi; Yoshie Omachi; Utako Nagaoka; Masahiro Nagao; Takashi Komori; Hisateru Tachimori; Shigeo Murayama; Hidehiro Mizusawa
Journal:  Aging Clin Exp Res       Date:  2021-07-20       Impact factor: 3.636

10.  The SORL1 gene and convergent neural risk for Alzheimer's disease across the human lifespan.

Authors:  D Felsky; P Szeszko; L Yu; W G Honer; P L De Jager; J A Schneider; A K Malhotra; T Lencz; T Ikuta; J Pipitone; M M Chakravarty; N J Lobaugh; B H Mulsant; B G Pollock; J L Kennedy; D A Bennett; A N Voineskos
Journal:  Mol Psychiatry       Date:  2013-10-29       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.